Medha Tomlinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Medha Tomlinson has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- David Banach
Department of Molecular & Cellular Pharmacology, Abbott Laboratories, Worcester, MA, USA
2 shared publications - David W. Borhani
Ginkgo Bioworks, Inc, MA, USA
2 shared publications - Douglas Marcotte
Chemical and Molecular Therapeutics, Biogen Inc, 250 Binney Street, Cambridge, MA, 02142, USA.
2 shared publications - Maria A. Argiriadi
Department of Molecular & Cellular Pharmacology, Abbott Laboratories, Worcester, MA, USA
2 shared publications - Robert V Talanian
Department of Molecular & Cellular Pharmacology, Abbott Laboratories, Worcester, MA, USA
2 shared publications - Silvino Sousa
Department of Biologics, Abbott Laboratories, Worcester, MA, USA
2 shared publications
Latest Publications
- Open Access
- 1 January 2012
- Published by Springer Nature in BMC Structural Biology
- Vol. 12 (1) , 22
Enabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor
Structure-based drug design (SBDD) can accelerate inhibitor lead design and optimization, and efficient methods including protein purification, characterization, crystallization, and high-resolution diffraction are all needed for rapid, iterative structure determination. Janus kinases are important targets that are amenable to structure-based drug design. Here we present the first mouse Tyk2 crystal structures, which are complexed to 3-aminoindazole compounds.
- 1 January 2012
- Published by Springer Nature in BMC Structural Biology
- Vol. 12 (1) , 22
Open AccessEnabling structure-based drug design of Tyk2 through co-crystallization with a stabilizing aminoindazole inhibitor
Structure-based drug design (SBDD) can accelerate inhibitor lead design and optimization, and efficient methods including protein purification, characterization, crystallization, and high-resolution diffraction are all needed for rapid, iterative structure determination. Janus kinases are important targets that are amenable to structure-based drug design. Here we present the first mouse Tyk2 crystal structures, which are complexed to 3-aminoindazole compounds.
- Open Access
- 1 January 2009
- Published by Springer Nature in BMC Structural Biology
- Vol. 9 (1) , 16
Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study
Structure-based drug design (SBDD) can provide valuable guidance to drug discovery programs. Robust construct design and expression, protein purification and characterization, protein crystallization, and high-resolution diffraction are all needed for rapid, iterative inhibitor design. We describe here robust methods to support SBDD on an oral anti-cytokine drug target, human MAPKAP kinase 2 (MK2). Our goal was to obtain useful diffraction data with a large number of chemically diverse lead compounds. Although MK2 structures and structural methods have been reported previously, reproducibility was low and improved methods were needed.
- 1 January 2009
- Published by Springer Nature in BMC Structural Biology
- Vol. 9 (1) , 16
Open AccessRational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study
Structure-based drug design (SBDD) can provide valuable guidance to drug discovery programs. Robust construct design and expression, protein purification and characterization, protein crystallization, and high-resolution diffraction are all needed for rapid, iterative inhibitor design. We describe here robust methods to support SBDD on an oral anti-cytokine drug target, human MAPKAP kinase 2 (MK2). Our goal was to obtain useful diffraction data with a large number of chemically diverse lead compounds. Although MK2 structures and structural methods have been reported previously, reproducibility was low and improved methods were needed.